Weekly cisplatin ± glutathione in relapsed ovarian carcinoma

N. Colombo, S. Bini, D. Miceli, G. Bogliun, L. Marzorati, G. Cavaletti, F. Parmigiani, P. Venturino, M. Tedeschi, L. Frattola, C. Buratti, C. Mangioni

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

On the basis of experimental data showing the efficacy of glutathione (GSH) as a protective agent on cisplatin-induced neurotoxicity and the clinical evidence of the low incidence of neurotoxicity in high-dose cisplatin + GSH treated patients we evaluated the neuroprotective effect of GSH in a randomized phase II study. Thirty-three patients with relapsed ovarian cancer after a disease-free interval of at least 1 year and a cumulative dose of prior cisplatin ranging 450-650 mg m-2 were randomized to receive cisplatin 50 mg m-2 weekly±2.5 g GSH for 9 consecutive weeks. Clinical and instrumental neurologic and otologic evaluations were made at the baseline and at the end of the study. Overall response rate in 31 evaluable patients was: 9/15 in group A and 12/16 in group B, including 4/15 vs 7/16 complete responses. The administered dose intensity of cisplatin was higher in the GSH treated patients (100% dose intensity was received by 56% vs 27%). A trend in terms of neuroprotection was detected in the GSH treated group, and no major difference was observed in the other toxicities between the two groups. It is concluded that possible benefit can be expected from the concomitant administration of GSH and cisplatin in patients at high risk of developing neurotoxicity, without decreasing the anti-tumor activity.

Original languageEnglish
Pages (from-to)81-86
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume5
Issue number2
DOIs
Publication statusPublished - 1995

Fingerprint

Cisplatin
Glutathione
Carcinoma
Protective Agents
Neuroprotective Agents
Ovarian Neoplasms
Nervous System
Incidence
Neoplasms

Keywords

  • cisplatin
  • dose-intensity
  • glutathione
  • relapsed ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Cancer Research

Cite this

Weekly cisplatin ± glutathione in relapsed ovarian carcinoma. / Colombo, N.; Bini, S.; Miceli, D.; Bogliun, G.; Marzorati, L.; Cavaletti, G.; Parmigiani, F.; Venturino, P.; Tedeschi, M.; Frattola, L.; Buratti, C.; Mangioni, C.

In: International Journal of Gynecological Cancer, Vol. 5, No. 2, 1995, p. 81-86.

Research output: Contribution to journalArticle

Colombo, N, Bini, S, Miceli, D, Bogliun, G, Marzorati, L, Cavaletti, G, Parmigiani, F, Venturino, P, Tedeschi, M, Frattola, L, Buratti, C & Mangioni, C 1995, 'Weekly cisplatin ± glutathione in relapsed ovarian carcinoma', International Journal of Gynecological Cancer, vol. 5, no. 2, pp. 81-86. https://doi.org/10.1046/j.1525-1438.1995.05020081.x
Colombo, N. ; Bini, S. ; Miceli, D. ; Bogliun, G. ; Marzorati, L. ; Cavaletti, G. ; Parmigiani, F. ; Venturino, P. ; Tedeschi, M. ; Frattola, L. ; Buratti, C. ; Mangioni, C. / Weekly cisplatin ± glutathione in relapsed ovarian carcinoma. In: International Journal of Gynecological Cancer. 1995 ; Vol. 5, No. 2. pp. 81-86.
@article{e620a9bc6b5c48d787b5449b24423b41,
title = "Weekly cisplatin ± glutathione in relapsed ovarian carcinoma",
abstract = "On the basis of experimental data showing the efficacy of glutathione (GSH) as a protective agent on cisplatin-induced neurotoxicity and the clinical evidence of the low incidence of neurotoxicity in high-dose cisplatin + GSH treated patients we evaluated the neuroprotective effect of GSH in a randomized phase II study. Thirty-three patients with relapsed ovarian cancer after a disease-free interval of at least 1 year and a cumulative dose of prior cisplatin ranging 450-650 mg m-2 were randomized to receive cisplatin 50 mg m-2 weekly±2.5 g GSH for 9 consecutive weeks. Clinical and instrumental neurologic and otologic evaluations were made at the baseline and at the end of the study. Overall response rate in 31 evaluable patients was: 9/15 in group A and 12/16 in group B, including 4/15 vs 7/16 complete responses. The administered dose intensity of cisplatin was higher in the GSH treated patients (100{\%} dose intensity was received by 56{\%} vs 27{\%}). A trend in terms of neuroprotection was detected in the GSH treated group, and no major difference was observed in the other toxicities between the two groups. It is concluded that possible benefit can be expected from the concomitant administration of GSH and cisplatin in patients at high risk of developing neurotoxicity, without decreasing the anti-tumor activity.",
keywords = "cisplatin, dose-intensity, glutathione, relapsed ovarian cancer",
author = "N. Colombo and S. Bini and D. Miceli and G. Bogliun and L. Marzorati and G. Cavaletti and F. Parmigiani and P. Venturino and M. Tedeschi and L. Frattola and C. Buratti and C. Mangioni",
year = "1995",
doi = "10.1046/j.1525-1438.1995.05020081.x",
language = "English",
volume = "5",
pages = "81--86",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Weekly cisplatin ± glutathione in relapsed ovarian carcinoma

AU - Colombo, N.

AU - Bini, S.

AU - Miceli, D.

AU - Bogliun, G.

AU - Marzorati, L.

AU - Cavaletti, G.

AU - Parmigiani, F.

AU - Venturino, P.

AU - Tedeschi, M.

AU - Frattola, L.

AU - Buratti, C.

AU - Mangioni, C.

PY - 1995

Y1 - 1995

N2 - On the basis of experimental data showing the efficacy of glutathione (GSH) as a protective agent on cisplatin-induced neurotoxicity and the clinical evidence of the low incidence of neurotoxicity in high-dose cisplatin + GSH treated patients we evaluated the neuroprotective effect of GSH in a randomized phase II study. Thirty-three patients with relapsed ovarian cancer after a disease-free interval of at least 1 year and a cumulative dose of prior cisplatin ranging 450-650 mg m-2 were randomized to receive cisplatin 50 mg m-2 weekly±2.5 g GSH for 9 consecutive weeks. Clinical and instrumental neurologic and otologic evaluations were made at the baseline and at the end of the study. Overall response rate in 31 evaluable patients was: 9/15 in group A and 12/16 in group B, including 4/15 vs 7/16 complete responses. The administered dose intensity of cisplatin was higher in the GSH treated patients (100% dose intensity was received by 56% vs 27%). A trend in terms of neuroprotection was detected in the GSH treated group, and no major difference was observed in the other toxicities between the two groups. It is concluded that possible benefit can be expected from the concomitant administration of GSH and cisplatin in patients at high risk of developing neurotoxicity, without decreasing the anti-tumor activity.

AB - On the basis of experimental data showing the efficacy of glutathione (GSH) as a protective agent on cisplatin-induced neurotoxicity and the clinical evidence of the low incidence of neurotoxicity in high-dose cisplatin + GSH treated patients we evaluated the neuroprotective effect of GSH in a randomized phase II study. Thirty-three patients with relapsed ovarian cancer after a disease-free interval of at least 1 year and a cumulative dose of prior cisplatin ranging 450-650 mg m-2 were randomized to receive cisplatin 50 mg m-2 weekly±2.5 g GSH for 9 consecutive weeks. Clinical and instrumental neurologic and otologic evaluations were made at the baseline and at the end of the study. Overall response rate in 31 evaluable patients was: 9/15 in group A and 12/16 in group B, including 4/15 vs 7/16 complete responses. The administered dose intensity of cisplatin was higher in the GSH treated patients (100% dose intensity was received by 56% vs 27%). A trend in terms of neuroprotection was detected in the GSH treated group, and no major difference was observed in the other toxicities between the two groups. It is concluded that possible benefit can be expected from the concomitant administration of GSH and cisplatin in patients at high risk of developing neurotoxicity, without decreasing the anti-tumor activity.

KW - cisplatin

KW - dose-intensity

KW - glutathione

KW - relapsed ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0028988236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028988236&partnerID=8YFLogxK

U2 - 10.1046/j.1525-1438.1995.05020081.x

DO - 10.1046/j.1525-1438.1995.05020081.x

M3 - Article

VL - 5

SP - 81

EP - 86

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 2

ER -